stoxline Quote Chart Rank Option Currency Glossary
  
Century Therapeutics, Inc. (IPSC)
4.18  -0.09 (-2.11%)    03-28 16:00
Open: 4.23
High: 4.32
Volume: 170,891
  
Pre. Close: 4.27
Low: 4.05
Market Cap: 271(M)
Technical analysis
2024-03-28 4:52:16 PM
Short term     
Mid term     
Targets 6-month :  5.51 1-year :  6.43
Resists First :  4.72 Second :  5.51
Pivot price 4.64
Supports First :  3.44 Second :  2.86
MAs MA(5) :  4.17 MA(20) :  4.61
MA(100) :  3.34 MA(250) :  2.97
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  15.8 D(3) :  12.4
RSI RSI(14): 45.7
52-week High :  5.51 Low :  1.27
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ IPSC ] has closed above bottom band by 19.8%. Bollinger Bands are 23.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.4 - 4.43 4.43 - 4.45
Low: 3.98 - 4.01 4.01 - 4.04
Close: 4.13 - 4.18 4.18 - 4.22
Company Description

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Headline News

Tue, 19 Mar 2024
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference - GlobeNewswire

Fri, 15 Mar 2024
Century Therapeutics Inc (IPSC) is lower by -5.53% in a Week, Should You Hold? - InvestorsObserver

Thu, 14 Mar 2024
IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023 - InvestorPlace

Fri, 08 Mar 2024
Century Therapeutics Inc (IPSC) COO Adrienne Farid Sells 53,515 Shares - Yahoo Finance

Wed, 06 Mar 2024
Is Century Therapeutics Inc (IPSC) Stock About to Get Hot Wednesday? - InvestorsObserver

Tue, 05 Mar 2024
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer ... - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 65 (M)
Held by Insiders 2.636e+007 (%)
Held by Institutions 36.4 (%)
Shares Short 846 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.1214e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -11 %
Return on Assets (ttm) 424.2 %
Return on Equity (ttm) -18.5 %
Qtrly Rev. Growth 2.23e+006 %
Gross Profit (p.s.) -37.39
Sales Per Share -43.14
EBITDA (p.s.) 0
Qtrly Earnings Growth -2.3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -88 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0.1
Price to Book value 0
Price to Sales -0.1
Price to Cash Flow 1.77
Stock Dividends
Dividend 0
Forward Dividend 1.75e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android